cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.22002/zmq6b-y1j90
title: Coxiella_burnetii_ wtACCMD_pH4d5

description: Coxiella burnetii Nine Mile phase II clone 4 (NMIIC4) strain. Wild-type cells day-5 culture. Cells grown in acidic media ACCMD and pH 4.75
description: <strong>Tilt Series Date:</strong> 2017-10-17</p>
<strong>Data Taken By:</strong> Debnath Ghosal</p>
<strong>Species / Specimen:</strong> Coxiella burnetii</p>
<strong>Strain:</strong> Nine Mile phase II clone 4</p>
<strong>Tilt Series Settings:</strong>  Single Axis, tilt range: (-60.0°, 60.0°), step: 2°, constant angular increment, dosage: 130.0 eV/Å²,  defocus: -7.0 μm,  magnification: 27500x. </p>
<strong>Microscope:</strong> Caltech Polara</p>
<strong>Acquisition Software:</strong> UCSFTomo</p>
<strong>Upload Method:</strong> pipeline</p>
<strong>Processing Software Used:</strong> Raptor</p>
<strong>Collaborators and Roles:</strong> Strain sent to us by Robert Heinzen. Data collected and processed by Debnath Ghosal and Mohammed Kaplan using Caltech tomography pipeline.</p>
<strong>Purification / Growth Conditions / Treatment:</strong> Cells were grown in Robert Heinzen's lab @NIAID and ~50 ul cells were sent to us.</p>
<strong>Sample Preparation:</strong> Refer to Heinzen lab. Freezing: 100% humidity, 4µl sample, Blot force 6, blot time 4 sec. Wait time 0 sec. Drain time 1 sec. Ethane/propane mix. Grid: Quantifoil Cu 2/2 200. Add gold to cells prior to freezing: 1ul of gold to 4 ul of cells, freeze.</p>
description: Files available via S3 at https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2017-10-17-18/rawdata/</p>Cb_d5pH4_201710170012.mrc,  Tilt Series (Pixel Size 0.39 nm), 1.7 GB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2017-10-17-18/rawdata/Cb_d5pH4_201710170012.mrc"
        > <i class="download icon"></i> Download </a></p>

        Cb_d5pH4_201710170012_full.rec,  Reconstruction (Pixel Size 1.56 nm), 445.4 MB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/dga2017-10-17-18/3dimage_89204/Cb_d5pH4_201710170012_full.rec"
        > <i class="download icon"></i> Download </a></p>
DOI: 10.15468/dl.y38ws6
title: Occurrence Download

description: A dataset containing 279 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Baileychromis centropomoides, Barboides gracilis, Barbopsis devecchii, Barbus hondeensis, Enteromius manicensis, Barbus kamaia, Enteromius motebensis, Barbus microbarbis, Labeobarbus microbarbis, Barbus microterolepis, Labeobarbus microterolepis, Barbus myersi, Enteromius radiatus, Barbus paucisquamatus, Labeobarbus paucisquamatus, Barbus tetraspilus, Barilius shariensis, Raiamas shariensis, Bathyaethiops breuseghemi, Bathyaethiops caudomaculatus, Bathyaethiops greeni, Bathybagrus grandis, Bathybagrus graueri, Bathybagrus platycephalus, Bathybagrus sianenna, Bathybagrus stappersii, Bathybagrus tetranema, Bathybates fasciatus, Bathybates ferox, Bathybates graueri, Bathybates hornii, Bathybates leo, Bathybates minor, Bathybates vittatus, Bathyclarias atribranchus, Bathyclarias euryodon, Bathyclarias filicibarbis, Bathyclarias foveolatus, Bathyclarias longibarbis, Bathyclarias nyasensis, Bathyclarias rotundifrons, Bathyclarias worthingtoni, Bathygobius casamancus, Bathygobius fuscus, Bathygobius petrophilus, Bathygobius samberanoensis, Bathygobius soporator, Bedotia albomarginata, Bedotia alveyi, Bedotia geayi, Bedotia leucopteron, Bedotia longianalis, Bedotia madagascariensis, Bedotia marojejy, Bedotia masoala, Bedotia tricolor, Belonoglanis brieni, Belonoglanis tenuis, Belonophago hutsebouti, Belonophago tinanti, Benitochromis batesii, Benitochromis conjunctus, Benitochromis finleyi, Benitochromis nigrodorsalis, Benitochromis riomuniensis, Benitochromis ufermanni, Benthochromis melanoides, Benthochromis tricoti, Boleophthalmus boddarti, Bostrychus africanus, Boulengerochromis microlepis, Boulengeromyrus knoepffleri, Brachyalestes bimaculatus, Brachyalestes carolinae, Brachyalestes comptus, Brachyalestes fwaensis, Brachyalestes imberi, Brycinus imberi, Brachyalestes jacksonii, Brachyalestes kingsleyae, Brachyalestes nurse, Brachypetersius altus, Brachypetersius cadwaladeri, Brachypetersius gabonensis, Brachypetersius huloti, Brachypetersius pseudonummifer, Brevimyrus niger, Brienomyrus brachyistius)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "BasisOfRecord is one of (Specimen, Living Specimen, Observation, Human Observation, Machine Observation, Material sample, Literature Occurrence, Material citation, Occurrence evidence)",
 "Geometry POLYGON ((28.1382 -6.9401,19.1382 -6.9401,19.1382 -15.9401,28.1382 -15.9401,28.1382 -6.9401))"
 ]
}

 The dataset includes 279 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0005979-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.22002/xmhbb-yxd38
title: V. cholerae JAS288 delta-tcpQ

description: Classical strain with ctxA deletionStrain name JAS288 (tcpQ gene knonkout)Cell harbors pMT5 plasmid (inducible toxT)
description: <strong>Tilt Series Date:</strong> 2016-09-14</p>
<strong>Data Taken By:</strong> Yi-Wei Chang</p>
<strong>Species / Specimen:</strong> Vibrio cholerae</p>
<strong>Strain:</strong> O395-N1</p>
<strong>Tilt Series Settings:</strong>  Single Axis, tilt range: (-60.0°, 60.0°), step: 1.0°, constant angular increment, dosage: 145.0 eV/Å²,  defocus: -6.0 μm,  magnification: 27500x. </p>
<strong>Microscope:</strong> Caltech Polara</p>
<strong>Acquisition Software:</strong> UCSFTomo</p>
<strong>Upload Method:</strong> pipeline</p>
<strong>Processing Software Used:</strong> Raptor</p>
<strong>Collaborators and Roles:</strong> Strain from Gabriela Kovacikova</p>
<strong>Purification / Growth Conditions / Treatment:</strong> O/N cultures of Vibrio cholerae O395 N1 pMT5 grown in LB, 1 mM IPTG and 100 ug/mL ampicillin.</p>
<strong>Sample Preparation:</strong> Vitrobot (MK iv) settings: 100% humidity, 3.5µl sample, 10 mg/ml BSA treated gold. Blot force 6, blot time 3 sec. Wait time 0 sec. Drain time 1 sec. Ethane/propane mix. Grid: Quantifoil Cu 2/2 200.</p>
description: Files available via S3 at https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/ycw2016-09-14-6/rawdata/</p>20160914_YWC216_10006.mrc,  Tilt Series (Pixel Size 0.39 nm), 3.4 GB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/ycw2016-09-14-6/rawdata/20160914_YWC216_10006.mrc"
        > <i class="download icon"></i> Download </a></p>

        20160914_YWC216_10006_full.rec,  Reconstruction (Pixel Size 1.56 nm), 534.5 MB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/ycw2016-09-14-6/3dimage_79065/20160914_YWC216_10006_full.rec"
        > <i class="download icon"></i> Download </a></p>
DOI: 10.22002/82mtg-s6c92
title: V. cholerae RT4236 (stationary)

description: Classical strain with ctxA deletion.Cell harbors pMT5 plasmid (inducible toxT).
description: <strong>Tilt Series Date:</strong> 2015-05-11</p>
<strong>Data Taken By:</strong> Yi-Wei Chang</p>
<strong>Species / Specimen:</strong> Vibrio cholerae</p>
<strong>Strain:</strong> O395-N1</p>
<strong>Tilt Series Settings:</strong>  Single Axis, tilt range: (-60.0°, 60.0°), step: 1.0°, constant angular increment, dosage: 180.0 eV/Å²,  defocus: -6.0 μm,  magnification: 27500x. </p>
<strong>Microscope:</strong> Caltech Polara</p>
<strong>Acquisition Software:</strong> UCSFTomo</p>
<strong>Upload Method:</strong> reupload_downloaded</p>
<strong>Processing Software Used:</strong> SIRT</p>
<strong>Collaborators and Roles:</strong> Strain from Ronald K. Taylor</p>
<strong>Purification / Growth Conditions / Treatment:</strong> Overnight cultures of Vibrio cholerae O395 NI pMT5 grown in LB pH 6.5, 1 mM IPTG and 100 ug/mL ampicilin</p>
<strong>Sample Preparation:</strong> Vitrobot (MK iv) settings: 100% humidity, 3µl sample, 10 mg/ml BSA treated gold. Blot force 6, blot time 2.5 sec. Wait time 0 sec. Drain time 1 sec. Ethane/propane mix. Grid: Quantifoil Cu 2/2 finder.</p>
description: Files available via S3 at https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/ycw2015-05-11-1/3dimage_73298/</p>20150511_AK07_10001_SIRT_2K.rec,  Reconstruction (Pixel Size 0.0 nm), 5.7 GB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/ycw2015-05-11-1/3dimage_73298/20150511_AK07_10001_SIRT_2K.rec"
        > <i class="download icon"></i> Download </a></p>

        20150511_AK07_10001.mrc,  Tilt Series (Pixel Size 0.39 nm), 3.4 GB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/ycw2015-05-11-1/rawdata/20150511_AK07_10001.mrc"
        > <i class="download icon"></i> Download </a></p>
DOI: 10.22002/t2n9f-yk765
title: V. cholerae RT4236 (stationary)

description: Classical strain with ctxA deletionCell harbors pMT5 plasmid (inducible toxT)
description: <strong>Tilt Series Date:</strong> 2015-08-10</p>
<strong>Data Taken By:</strong> Yi-Wei Chang</p>
<strong>Species / Specimen:</strong> Vibrio cholerae</p>
<strong>Strain:</strong> O395-N1</p>
<strong>Tilt Series Settings:</strong>  Single Axis, tilt range: (-60.0°, 60.0°), step: 1.0°, constant angular increment, dosage: 160.0 eV/Å²,  defocus: -6.0 μm,  magnification: 27500x. </p>
<strong>Microscope:</strong> Caltech Polara</p>
<strong>Acquisition Software:</strong> UCSFTomo</p>
<strong>Upload Method:</strong> reupload_downloaded</p>
<strong>Processing Software Used:</strong> SIRT</p>
<strong>Collaborators and Roles:</strong> Strain from Ronald K. Taylor</p>
<strong>Purification / Growth Conditions / Treatment:</strong> Overnight cultures of Vibrio cholerae O395 NI pMT5 grown in LB pH 6.5, 1 mM IPTG and 100 ug/mL ampicilin. Take the sedimented cell clumps.</p>
<strong>Sample Preparation:</strong> Vitrobot (MK iv) settings: 100% humidity, 3µl sample, 10 mg/ml BSA treated gold. Blot force 6, blot time 2.5 sec. Wait time 0 sec. Drain time 1 sec. Ethane/propane mix. Grid: Quantifoil Cu 2/2 200.</p>
description: Files available via S3 at https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/ycw2015-08-10-41/3dimage_73159/</p>20150810_AK20_20041_SIRT_2K.rec,  Reconstruction (Pixel Size 0.0 nm), 14.2 GB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/ycw2015-08-10-41/3dimage_73159/20150810_AK20_20041_SIRT_2K.rec"
        > <i class="download icon"></i> Download </a></p>

        20150810_AK20_20041.mrc,  Tilt Series (Pixel Size 0.39 nm), 3.4 GB  
        
<a role="button" class="ui compact mini button" href="https://sdsc.osn.xsede.org/ini210004tommorrell/tomography_archive/ycw2015-08-10-41/rawdata/20150810_AK20_20041.mrc"
        > <i class="download icon"></i> Download </a></p>
DOI: 10.18712/nsd-nsd3320-v1
title: Questions to Norway's Kindergarten Sector, Owners, 2019

description: Questions to Norway's Kindergarten Sector 2019 present the results of an annual survey conducted by the Norwegian Directorate for Education and Training targeting the kindergarten sector. The survey has been carried out yearly since 2014. 

This year's survey covers the following topics:  
- Staffing and pedagogical standards  
- Competence and collaboration on kindergarten and school environments  
- Competence development programs such as *Inclusive Kindergarten and School Environment*  
- Preparedness and prevention of serious incidents  
- Language development  
- Transition from kindergarten to school  
- Social media  
- Mapping of parental support  
- The role of the kindergarten manager.

This file contains information about kindergarten owners.
DOI: 10.25345/c51n7z09z
title: MassIVE MSV000098973 - GNPS Screening the culture conditions for antibacterial compounds from Bacillus velezensis
title: Metabolites from different culture conditions of Bacillus velezensis. The purpose is to screen for antibacterial compounds against Flavobacteriaceae from Bacillus velezensis.
DOI: 10.6084/m9.figshare.30009307
title: <b>A coupled LBM-FDEM framework for simulating </b><b>solute transport and mineral dissolution </b><b>under H-M-C conditions</b>

description: This study introduces a multi-field coupled simulation framework that integrates the Lattice Boltzmann Method (LBM) with the Finite Discrete Element Method (FDEM) to model solute transport and mineral microstructure dissolution. To validate the developed LBM-FDEM coupling method, several numerical case studies are conducted. All the data curves, the dissolved pattern and the concentration and velocity distribution contour obtained from above numerical simulation results are all stored in this online repository.
DOI: 10.6084/m9.figshare.30009307.v1
title: <b>A coupled LBM-FDEM framework for simulating </b><b>solute transport and mineral dissolution </b><b>under H-M-C conditions</b>

description: This study introduces a multi-field coupled simulation framework that integrates the Lattice Boltzmann Method (LBM) with the Finite Discrete Element Method (FDEM) to model solute transport and mineral microstructure dissolution. To validate the developed LBM-FDEM coupling method, several numerical case studies are conducted. All the data curves, the dissolved pattern and the concentration and velocity distribution contour obtained from above numerical simulation results are all stored in this online repository.
DOI: 10.6084/m9.figshare.28945296
title: Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon’s ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: results from the Study to Test pharmacokinetic BioEquivalence of BiosimiLar ustekinumab to SteLARa (STELLAR-1)

description: This study assessed the pharmacokinetics (PK) equivalence, safety, tolerability, and immunogenicity of Bmab-1200 versus the reference product ustekinumab (EU-approved and US-licensed Stelara). This 20-week, randomized, double-blind, three-arm, parallel-design, Phase-1 study enrolled healthy male and female subjects (<i>n</i> = 258; 18–55 years). A single, 45-mg subcutaneous injection of Bmab-1200, EU-approved Stelara, or US-licensed Stelara was administered in a 1:1:1 ratio. Subject stratification was performed by ethnicity, body weight range, and gender. Primary PK endpoints included AUC<sub>0-inf</sub> and C<sub>max</sub>. Secondary endpoints included additional PK parameters, immunogenicity, and safety and tolerability. All three pairwise comparisons of Bmab-1200 versus US-Stelara, Bmab-1200 versus EU-Stelara, and US-Stelara versus EU-Stelara were equivalent for AUC<sub>0-inf</sub> (90% confidence intervals [CIs] of the geometric least squares mean [GLSM] ratio: 0.9975–1.1657, 0.9959–1.1685, and 0.9223–1.0921, respectively) and C<sub>max</sub> (90% CIs of the GLSM ratio: 0.9478–1.0732, 0.9136–1.0376, and 0.9012–1.0267, respectively). All secondary analyses supported the primary results. Three-way PK equivalence between Bmab-1200, US-Stelara, and EU-Stelara was demonstrated. A single, 45-mg dose of Bmab-1200 was safe and well tolerated, and, overall, the number of AEs was similar among the groups. Diversity limited to White and Japanese groups did not impact the study results. This study was registered with www.isrctn.com; identifier: ISRCTN11424009.
DOI: 10.6084/m9.figshare.28945296.v2
title: Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon’s ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: results from the Study to Test pharmacokinetic BioEquivalence of BiosimiLar ustekinumab to SteLARa (STELLAR-1)

description: This study assessed the pharmacokinetics (PK) equivalence, safety, tolerability, and immunogenicity of Bmab-1200 versus the reference product ustekinumab (EU-approved and US-licensed Stelara). This 20-week, randomized, double-blind, three-arm, parallel-design, Phase-1 study enrolled healthy male and female subjects (<i>n</i> = 258; 18–55 years). A single, 45-mg subcutaneous injection of Bmab-1200, EU-approved Stelara, or US-licensed Stelara was administered in a 1:1:1 ratio. Subject stratification was performed by ethnicity, body weight range, and gender. Primary PK endpoints included AUC<sub>0-inf</sub> and C<sub>max</sub>. Secondary endpoints included additional PK parameters, immunogenicity, and safety and tolerability. All three pairwise comparisons of Bmab-1200 versus US-Stelara, Bmab-1200 versus EU-Stelara, and US-Stelara versus EU-Stelara were equivalent for AUC<sub>0-inf</sub> (90% confidence intervals [CIs] of the geometric least squares mean [GLSM] ratio: 0.9975–1.1657, 0.9959–1.1685, and 0.9223–1.0921, respectively) and C<sub>max</sub> (90% CIs of the GLSM ratio: 0.9478–1.0732, 0.9136–1.0376, and 0.9012–1.0267, respectively). All secondary analyses supported the primary results. Three-way PK equivalence between Bmab-1200, US-Stelara, and EU-Stelara was demonstrated. A single, 45-mg dose of Bmab-1200 was safe and well tolerated, and, overall, the number of AEs was similar among the groups. Diversity limited to White and Japanese groups did not impact the study results. This study was registered with www.isrctn.com; identifier: ISRCTN11424009.
DOI: 10.6084/m9.figshare.28945296.v1
title: Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon’s ustekinumab (bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: results from the study to Test pharmacokinetic BioEquivalence of BiosimiLar ustekinumab to SteLARa (STELLAR-1)

description: This study assessed the pharmacokinetics (PK) equivalence, safety, tolerability, and immunogenicity of Bmab-1200 versus the reference product ustekinumab (EU-approved and US-licensed Stelara). This 20-week, randomized, double-blind, three-arm, parallel-design, Phase-1 study enrolled healthy male and female subjects (<i>n</i> = 258; 18-55 years). A single, 45-mg subcutaneous injection of Bmab-1200, EU-approved Stelara, or US-licensed Stelara was administered in a 1:1:1 ratio. Subject stratification was performed by ethnicity, body weight range, and gender. Primary PK endpoints included AUC<sub>0-inf</sub> and C<sub>max</sub>. Secondary endpoints included additional PK parameters, immunogenicity, and safety and tolerability. All three pairwise comparisons of Bmab-1200 versus US-Stelara, Bmab-1200 versus EU-Stelara, and US-Stelara versus EU-Stelara were equivalent for AUC<sub>0-inf</sub> (90% confidence intervals [CIs] of the geometric least squares mean [GLSM] ratio: 0.9975-1.1657, 0.9959-1.1685, and 0.9223-1.0921, respectively) and C<sub>max</sub> (90% CIs of the GLSM ratio: 0.9478-1.0732, 0.9136-1.0376, and 0.9012-1.0267, respectively). All secondary analyses supported the primary results. Three-way PK equivalence between Bmab-1200, US-Stelara, and EU-Stelara was demonstrated. A single, 45-mg dose of Bmab-1200 was safe and well tolerated, and overall, the number of AEs was similar among the groups. Diversity limited to white and Japanese groups did not impact the study results. This study was registered with www.isrctn.com identifier is (ISRCTN11424009).
DOI: 10.5281/zenodo.16994378
title: Direct and real-time metagenomic sequencing of target-amplified genomes (mTAGs) for public health surveillance: A preliminary laboratory trial

description: Supplementary File 1. Metadata associated with the finalized set of 1,004 reference genomes that represent a diverse range of clinically relevant strains of Shigatoxigenic Escherichia coli [STEC], Salmonella enterica subsp. enterica, Enterococcus faecalis, Enterococcus faecium, Campylobacter jejuni, Campylobacter coli, and Campylobacter lari used as the basis for in silico construction of probe panels for application in mTAG sequencing.

Supplementary File 2. Probe file (.FASTA) of the finalized 120-mer bait sequences obtained from in silico construction via the Syotti algorithm, and served as the basis for manufacturing and use of biotinylated probes in mTAG sequencing.
DOI: 10.5281/zenodo.16994379
title: Direct and real-time metagenomic sequencing of target-amplified genomes (mTAGs) for public health surveillance: A preliminary laboratory trial

description: Supplementary File 1. Metadata associated with the finalized set of 1,004 reference genomes that represent a diverse range of clinically relevant strains of Shigatoxigenic Escherichia coli [STEC], Salmonella enterica subsp. enterica, Enterococcus faecalis, Enterococcus faecium, Campylobacter jejuni, Campylobacter coli, and Campylobacter lari used as the basis for in silico construction of probe panels for application in mTAG sequencing.

Supplementary File 2. Probe file (.FASTA) of the finalized 120-mer bait sequences obtained from in silico construction via the Syotti algorithm, and served as the basis for manufacturing and use of biotinylated probes in mTAG sequencing.
DOI: 10.5517/ccdc.csd.cc2l40g7
title: CCDC 2387138: Experimental Crystal Structure Determination

description: Related Article: Alec T. Larson, Serhii Vasylevskyi, Michael J. Rose|2025|J.Am.Chem.Soc.|147|27341|doi:10.1021/jacs.5c02268
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.6084/m9.figshare.30010282
title: Data for : Comparative Efficacy and Safety of Different Combination Therapies for Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis

description: This dataset contains the extracted data for the systematic review and network meta-analysis (NMA) entitled "Comparative Efficacy and Safety of Different Combination Therapies for Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis"The included files are:1.extracted_data_outcomes:The raw, study-level data extracted for all efficacy and safety outcomes used in the meta-analysis. This is the primary input data for all statistical analyses.2.Baseline Patient Characteristics:A summary table of the baseline characteristics of the included studies and their patient populations.3.Risk of bias assessment:The risk of bias assessment for each included randomized controlled trial, performed using the Cochrane Risk of Bias tool.The NMA compared the efficacy and safety of contemporary regimens including VRd, DRd, KRd, VCd, etc., for patients with newly diagnosed multiple myeloma (NDMM). Outcomes include progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and key adverse events (AEs).For a detailed explanation of variables, please refer to the accompanying README file.